Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.83, for a total transaction of $538,721.61. Following the completion of the transaction, the chief financial officer now owns 473,433 shares of the company’s stock, valued at approximately $9,388,176.39. This trade represents a 5.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Arrowhead Pharmaceuticals Stock Up 0.9 %

Arrowhead Pharmaceuticals stock traded up $0.17 during mid-day trading on Tuesday, reaching $19.67. 1,197,900 shares of the company’s stock were exchanged, compared to its average volume of 1,241,250. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83. The company has a fifty day moving average of $21.03 and a 200-day moving average of $22.56. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a market cap of $2.45 billion, a P/E ratio of -3.92 and a beta of 0.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Meeder Asset Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $149,000. Finally, Quarry LP grew its position in shares of Arrowhead Pharmaceuticals by 54.5% during the second quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 3,000 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARWR has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.